Vilei M T, Granato A, Ferraresso C, Neri D, Carraro P, Gerunda G, Muraca M
Department of Medical and Surgical Sciences, University of Padova, Italy.
Int J Artif Organs. 2001 Jun;24(6):392-6.
The limited availability of human hepatocytes results in the use of animal cells in most bioartificial liver support devices. In the present work, clinically relevant liver specific metabolic activities were compared in rat, pig and human hepatocytes cultured on liver-derived biomatrix to optimize the expression of differentiated functions. Pig hepatocytes showed higher rates of diazepam metabolism (2.549+/-0.821 microg/h/million cells vs. 0.474+/-0.079 microg/h/million cells rats, p<0.005, and vs. 0.704+/-0.171 microg/h/million cells in man, p<0.005) and of bilirubin conjugation (21.60116+/-8.433237 micromoles/l/24 h vs. 6.786809+/-2.983758 in man, p<0.001 and vs. 9.956538+/-1.781016 micromoles/l/24 h in rats, p<0.005). Urea synthesis was similar in pig and in human hepatocytes (150+/-46.3 vs. 144.8+/-21.46 nmoles/h/million cells) and it was lower in rats (84.38+/-35.2; p<0.001 vs. man, p<0.02 vs. pig). High liver specific metabolic activities in cultured pig hepatocytes further support their use as a substitue for human cells in bioartificial liver devices.
人类肝细胞的有限可用性导致大多数生物人工肝支持装置中使用动物细胞。在本研究中,比较了在肝脏来源的生物基质上培养的大鼠、猪和人类肝细胞中与临床相关的肝脏特异性代谢活性,以优化分化功能的表达。猪肝细胞的地西泮代谢率更高(2.549±0.821微克/小时/百万细胞,大鼠为0.474±0.079微克/小时/百万细胞,p<0.005,人类为0.704±0.171微克/小时/百万细胞,p<0.005),胆红素结合率也更高(21.60116±8.433237微摩尔/升/24小时,人类为6.786809±2.983758,p<0.001,大鼠为9.956538±1.781016微摩尔/升/24小时,p<0.005)。猪和人类肝细胞中的尿素合成相似(150±46.3对144.8±21.46纳摩尔/小时/百万细胞),而大鼠中的尿素合成较低(84.38±35.2;与人相比p<0.001,与猪相比p<0.02)。培养的猪肝细胞中高肝脏特异性代谢活性进一步支持将其用作生物人工肝装置中人类细胞的替代物。